Thermosome Announces First Patient Dosed in Phase I Trial with Lead Program THE001
May 24, 2023 04:00 ET | AKAMPION
-    Addressing high unmet medical need in locally advanced soft tissue sarcoma-    Targeted tumor treatment independent of specific molecular targets or tumor subtypes Munich, Germany – May 24,...
Thermosome Receives Regulatory Approval for First-In-Human Trial with its Lead Program THE001
March 28, 2023 03:45 ET | AKAMPION
-   Novel compound for targeted tumor therapy to be evaluated in patients with soft tissue sarcoma-   First patients to be enrolled in Q2, 2023 Munich, Germany – March 28, 2023 – Thermosome, a...
MNPR Triangle 2.JPG
Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma
October 27, 2021 08:05 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Philogen logo.png
Philogen Provides Corporate Update
September 29, 2021 04:58 ET | Philogen
Philogen Provides Corporate Update Nidlegy™ and Fibromun on track with planned timelines in pivotal clinical trialsUse of Nidlegy™ in non-melanoma skin cancer expanded in Phase II clinical...
The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030, growing at an annualized rate of 27.54% during the period 2021-2030, claims Roots Analysis
September 22, 2021 09:00 ET | Roots Analysis
London, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Soft Tissue Sarcoma Market: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report...
FINAL Rafafel_Pharma_PHP_LOGO_Updated 05042020_V3 (1).png
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma
October 29, 2020 09:30 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics announced today that...
TLC_Tagline EN.png
TLC to Present Preclinical Data on TLC178 at ESMO 2019
September 23, 2019 05:00 ET | TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 23, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
EMA Grants Orphan Drug Designation to TLC178 for the Treatment of Soft Tissue Sarcoma
January 22, 2019 06:00 ET | Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated...
Logo new.jpg
Vivos Inc. to Treat Advanced Canine Patient for Soft Tissue Sarcoma with IsoPet®
December 04, 2018 15:50 ET | Vivos Inc.
Richland, WA, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTC PINK: RDGL) a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in...